<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Invivyd Inc. — News on 6ix</title>
<link>https://6ix.com/company/invivyd-inc</link>
<description>Latest news and press releases for Invivyd Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 11:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/invivyd-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835868e78dffbe2df0fdff5.webp</url>
<title>Invivyd Inc.</title>
<link>https://6ix.com/company/invivyd-inc</link>
</image>
<item>
<title>Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit</title>
<link>https://6ix.com/company/invivyd-inc/news/invivyd-announces-chairman-marc-elia-to-speak-at-politico-health-care-summit</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/invivyd-announces-chairman-marc-elia-to-speak-at-politico-health-care-summit</guid>
<pubDate>Mon, 20 Apr 2026 11:01:00 GMT</pubDate>
<description>Elia to speak at the premier gathering of policy makers, industry leaders, and health experts between 11:30 AM ET – 12:00 PM ET on April 21Event to be live streamed between 9:00 AM – 1:00 PM ET NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc Elia, Chairman of the Invivyd Board of Directors, is a featured speaker at the POLITICO Health Care Summit on Tuesday, April 21. During the session, Mr. Elia will frame the evolving landscape of vir</description>
</item>
<item>
<title>Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles</title>
<link>https://6ix.com/company/invivyd-inc/news/invivyd-announces-revolution-program-progress-and-advancement-of-novel-potential-first-and-best-in-class-measles-monoclonal-antibody-candidate-vms063-for-treatment-and-prevention-of-measles</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/invivyd-announces-revolution-program-progress-and-advancement-of-novel-potential-first-and-best-in-class-measles-monoclonal-antibody-candidate-vms063-for-treatment-and-prevention-of-measles</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>Confirmed, pooled, blinded COVID-19 events in the ongoing Phase 3 DECLARATION study of VYD2311 accumulated to date (~ 50% of study progress) can already</description>
</item>
<item>
<title>Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health</title>
<link>https://6ix.com/company/invivyd-inc/news/invivyd-launches-antibodies-for-any-body-in-partnership-with-world-champion-skier-lindsey-vonn-to-inspire-actions-that-help-support-immune-health</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/invivyd-launches-antibodies-for-any-body-in-partnership-with-world-champion-skier-lindsey-vonn-to-inspire-actions-that-help-support-immune-health</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>National education campaign aims to educate Americans about antibodies and their role in immune healthCampaign centerpiece, AntibodiesforAnyBody.com, offers</description>
</item>
<item>
<title>Invivyd Announces Presentation at the World Vaccine Congress Washington</title>
<link>https://6ix.com/company/invivyd-inc/news/invivyd-announces-presentation-at-the-world-vaccine-congress-washington</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/invivyd-announces-presentation-at-the-world-vaccine-congress-washington</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Chief Scientific Officer, Robert Allen, Ph.D., presented as part of the “Antibodies for Infectious Disease Workshop” at the World Vaccine Congress</description>
</item>
<item>
<title>Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates</title>
<link>https://6ix.com/company/invivyd-inc/news/invivyd-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-recent-business-highlights-and-declaration-clinical-trial-updates-12</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/invivyd-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-recent-business-highlights-and-declaration-clinical-trial-updates-12</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025</description>
</item>
<item>
<title>Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer</title>
<link>https://6ix.com/company/invivyd-inc/news/invivyd-appoints-distinguished-physician-and-scientist-michael-mina-md-phd-as-chief-medical-officer-12</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/invivyd-appoints-distinguished-physician-and-scientist-michael-mina-md-phd-as-chief-medical-officer-12</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard</description>
</item>
<item>
<title>Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026</title>
<link>https://6ix.com/company/invivyd-inc/news/invivyd-to-host-fourth-quarter-and-full-year-2025-financial-results-and-corporate-update-conference-call-on-march-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/invivyd-to-host-fourth-quarter-and-full-year-2025-financial-results-and-corporate-update-conference-call-on-march-5-2026</guid>
<pubDate>Mon, 02 Mar 2026 21:10:00 GMT</pubDate>
<description>NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March 5, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and provide a corporate update. Interested parties may join the live webcast by visiting this link. Analysts wishing to participate in the question-and-a</description>
</item>
<item>
<title>Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/invivyd-inc/news/invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Mon, 02 Mar 2026 21:01:00 GMT</pubDate>
<description>NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on March 1, 2026, Invivyd granted four newly hired non-executive employees options to purchase an aggregate of 192,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan. The options have a per share exer</description>
</item>
<item>
<title>New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies</title>
<link>https://6ix.com/company/invivyd-inc/news/new-publication-demonstrates-variant-agnostic-correlate-of-protection-from-covid-19-for-invivyd-monoclonal-antibody-useful-for-understanding-of-and-confidence-in-covid-19-antibodies</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/new-publication-demonstrates-variant-agnostic-correlate-of-protection-from-covid-19-for-invivyd-monoclonal-antibody-useful-for-understanding-of-and-confidence-in-covid-19-antibodies</guid>
<pubDate>Tue, 24 Feb 2026 12:01:00 GMT</pubDate>
<description>“A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19” was published in Infectious Diseases and Therapy This peer-reviewed analysis describes the relationship between anti-COVID monoclonal antibody (mAb) levels in patient serum and demonstrated clinical protection from multiple Omicron-virus variants in a modern, COVID-endemic, seropositive population, adding t</description>
</item>
<item>
<title>Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration</title>
<link>https://6ix.com/company/invivyd-inc/news/invivyd-aligns-u-fda-liberty-120100670</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/invivyd-aligns-u-fda-liberty-120100670</guid>
<pubDate>Tue, 03 Feb 2026 12:01:00 GMT</pubDate>
<description>LIBERTY is part of the Company’s broader REVOLUTION clinical program designed to elaborate the profile of monoclonal antibody-mediated prophylaxis from COVID-19 and the potential medical benefits to vulnerable AmericansThe LIBERTY clinical trial will evaluate comparative safety and immunology of VYD2311 versus mRNA COVID vaccine, as well as explore the safety and immunology of co-administered VYD2311 and mRNA COVID vaccineFDA, providing feedback jointly from CDER and CBER, requested specific mon</description>
</item>
<item>
<title>Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention</title>
<link>https://6ix.com/company/invivyd-inc/news/invivyd-announces-partnership-world-champion-120100884</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/invivyd-announces-partnership-world-champion-120100884</guid>
<pubDate>Thu, 22 Jan 2026 12:01:00 GMT</pubDate>
<description>World champion skier Lindsey Vonn Invivyd announces partnership with world champion skier Lindsey Vonn to educate Americans on antibodies and disease prevention The educational campaign will focus on teaching the American public about antibodies and preventing infectious diseaseThe collaboration will advance public understanding of antibodies as a centerpiece of modern wellness strategiesMedia campaign planned to launch in spring 2026 following Ms. Vonn’s closely watched and inspiring comeback s</description>
</item>
<item>
<title>Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026</title>
<link>https://6ix.com/company/invivyd-inc/news/invivyd-spear-study-group-announce-120100008</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/invivyd-spear-study-group-announce-120100008</guid>
<pubDate>Tue, 20 Jan 2026 12:01:00 GMT</pubDate>
<description>Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injuryParticipants to include people with Long COVID who demonstrate evidence of chronic infection or antigen persistence in a variety of tissues, and COVID vaccine-injured people including those who have demonstrated persistence of vaccine-delivered spike proteinDesign includes multiple highly active antibody doses administered over the</description>
</item>
<item>
<title>Adimab Records Another Year of Double-Digit Clinical Program Growth</title>
<link>https://6ix.com/company/invivyd-inc/news/adimab-records-another-year-of-double-digit-clinical-program-growth</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/adimab-records-another-year-of-double-digit-clinical-program-growth</guid>
<pubDate>Tue, 13 Jan 2026 17:33:00 GMT</pubDate>
<description>Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that 11 new programs entered clinical trials in 2025. These 11 programs bring the total number of partner programs that have entered clinical trials to 89, including six therapeutic products containing molecules discovered or optimized using the Adimab platform which have been authorized for commercial sale.</description>
</item>
<item>
<title>Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights</title>
<link>https://6ix.com/company/invivyd-inc/news/invivyd-reports-preliminary-fourth-quarter-120100082</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/invivyd-reports-preliminary-fourth-quarter-120100082</guid>
<pubDate>Thu, 08 Jan 2026 12:01:00 GMT</pubDate>
<description>Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarterPreliminary ending 2025 cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted b</description>
</item>
<item>
<title>Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID</title>
<link>https://6ix.com/company/invivyd-inc/news/invivyd-earns-fast-track-designation-120500812</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/invivyd-earns-fast-track-designation-120500812</guid>
<pubDate>Tue, 23 Dec 2025 12:05:00 GMT</pubDate>
<description>NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an investigational vaccine-alternative monoclonal antibody candidate for the prevention of COVID. Fast Track is a process that enables the FDA to expedite the development and review of new drugs that address a serious or life-threatening condition and fill an unmet medical need. If relevant criteria are m</description>
</item>
<item>
<title>Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID</title>
<link>https://6ix.com/company/invivyd-inc/news/invivyd-announces-initiation-declaration-clinical-120100100</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/invivyd-announces-initiation-declaration-clinical-120100100</guid>
<pubDate>Tue, 23 Dec 2025 12:01:00 GMT</pubDate>
<description>DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID versus placebo, at three months, from a single intramuscular (IM) dose, with protection beyond three months anticipated A second arm will evaluate monthly IM doses versus placebo to demonstrate the safety and efficacy of more frequent dosing to support individual choice should at-risk persons seek periodic extra protection from COVIDPrimary endpoint is</description>
</item>
<item>
<title>Invivyd to Participate at the 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/invivyd-inc/news/invivyd-participate-8th-annual-evercore-120100802</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/invivyd-participate-8th-annual-evercore-120100802</guid>
<pubDate>Tue, 25 Nov 2025 12:01:00 GMT</pubDate>
<description>NEW HAVEN, Conn., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 2:35 p.m. ET in Miami, FL. A live webcast of the fireside chat will be available in the investor section of the company's website at investors.invivyd.com and will be archived for approximately 90 days following the presentation. About InvivydInvivyd, Inc. (Nasdaq: IVV</description>
</item>
<item>
<title>Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness</title>
<link>https://6ix.com/company/invivyd-inc/news/invivyd-announces-selection-potential-best-120100546</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/invivyd-announces-selection-potential-best-120100546</guid>
<pubDate>Mon, 24 Nov 2025 12:01:00 GMT</pubDate>
<description>VBY329 is designed for the prevention of Respiratory Syncytial Virus (RSV) infections in newborns, infants, and children, and results from Invivyd’s proprietary antibody discovery technology platformVBY329 meets Invivyd’s target profile of higher potency and improved barrier to resistance compared to standard of care RSV medicines, as assessed in vitro: Antiviral potency 1.5-fold greater on average than nirsevimab and 1.2-fold greater on average than clesrovimab against established authentic RSV</description>
</item>
<item>
<title>Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/invivyd-inc/news/invivyd-announces-pricing-125-million-034000393</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/invivyd-announces-pricing-125-million-034000393</guid>
<pubDate>Tue, 18 Nov 2025 03:40:00 GMT</pubDate>
<description>NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at an offering price of $2.50 per share and, to certain investors, in lieu of common stock, pre-funded warrants to purchase 6,000,000 shares of its common stock at a price of $2.4999 per pre-funded warrant. The gross proceeds from this offering are expected to be approximately $125.0 million, before dedu</description>
</item>
<item>
<title>Invivyd Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/invivyd-inc/news/invivyd-announces-proposed-public-offering-210100089</link>
<guid isPermaLink="true">https://6ix.com/company/invivyd-inc/news/invivyd-announces-proposed-public-offering-210100089</guid>
<pubDate>Mon, 17 Nov 2025 21:01:00 GMT</pubDate>
<description>NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the shares of Invivyd common stock sold in the public offering at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Inv</description>
</item>
</channel>
</rss>